[Invitation to Contributors]

Guided by Suzhou Municipal People’s Government, Great Wall Enterprise Institute (GEI) and Suzhou Industrial Park Administrative Committee (SIPAC) jointly held the Press Conference on the Release of 2022 China Potential Unicorns Report, at which 2022 China Potential Unicorns Research Report was released formally.

Beijing CytoNiche Technology Co., Ltd. (“CytoNiche”) was rated as one of “2021 GEI China Potential Unicorns” for its proactive innovation and exploration in 3D cell culture technology as well as its aggressive vision in the cutting-edge pipeline of CDMO business.

Table: 2021 GEI China Potential Unicorns (not inclusive)

As leaders of the new track, potential unicorns reshape the value chain by means of new technologies and models, explore new markets and create new business forms by means of scenario innovation.

[Criteria for GEI China Potential Unicorns]

① Enterprises registered in China with legal personality;

② Enterprises meeting any one of the following conditions: the post-valuation reaches USD 100 million at the last round of financing within five years upon its establishment;

③ Enterprises having received private investment but not yet been listed.

[Selection Procedure of GEI China Potential Unicorns]

①Follow the criteria for unicorns under GB/T 41464-2022 Directives for Classification of High-growth Enterprises;

②Consolidate the data of candidate enterprises that are applied by enterprise themselves, recommended by investors or SIP, screened through GEI database, supported by third-party data or collected through public data;

③Review and screen the 2021 China Potential Unicorns that meet the criteria combined with visits to key enterprises.

As typical representatives of new economy enterprises, potential unicorns have been playing an increasingly important role in boosting quality development of regional economy and promoting the conversion of economic engines. CytoNiche, a hi-tech company in China and an SRDI (Specialized, Refinement, Differential, Innovation) Company in Beijing, is now rated as one of China Potential Unicorns. This demonstrates that CytoNiche has achieved outstanding achievements in terms of its innovation vitality, its technology gene, and its real economy attributes as well as its positive role in opening up new fields and developing new drivers of economy.

Going forward, CytoNiche, upholding its vision for opening a new era of cell industrialization development, will be devoted itself to the development and landing of relevant technologies in 3D cell “intelligent manufacturing” and regenerative medicine in the field of biomedicine, will advance the deep integration of the cell industry and its derivatives with social development, will make more efforts on the industrial innovation and enhance its model and leading role across the industry.

【CytoNiche】

Beijing CytoNiche Biotechnology Co., Ltd. was established by the research team of Professor Du Yanan from Tsinghua University School of Medicine, and was jointly established by Tsinghua University through equity participation. The core technologies were derived from the transformation of scientific and technological achievements of Tsinghua University. CytoNiche focuses on building an original 3D cell "smart manufacturing" platform, as well as providing overall solutions for the 3D microcarrier-based customized cell amplification process.

CytoNiche's core product, 3D TableTrix® Microcarrier Tablet (Microcarrier), is an independent innovation and the first pharmaceutical excipient grade microcarrier that can be used for cell drug development. It has obtained the certificate of analysis from relevant authoritative institutions such as National Institutes for Food and Drug Control, and obtained 2 qualifications for pharmaceutical excipients from the National Medical Products Administration (CDE approval registration number: F20210000003, F20200000496). Moreover, the product has obtained the DMF qualification for pharmaceutical excipients from U.S. FDA (DMF: 35481). 

Products and services of CytoNiche can be widely used in the upstream process development of gene and cell therapy, extracellular vesicles, vaccines, and protein products. At the same time, it also has broad prospects for applications in the fields of regenerative medicine, organoids, and food technology (cell-cultured meat, etc.).

Our company has a R&D and transformation platform of 5,000 square meters, including a CDMO platform of more than 1,000 square meters, a GMP production platform of 4,000 square meters, and a new 1200 L microcarrier production line. The relevant technologies have obtained more than 100 patents and more than 30 articles about the technologies in international journals have been published. The core technology projects have obtained a number of national-level project support and applications.